AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

CNBCJuly 11, 2026 at 5:00 AM

For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.

This is a summary. For the full story, read the original article at CNBC.

Original source: CNBC

markets

Inflation is broadening out, says Goldman economist

MarketWatchJuly 20, 2026 at 9:32 AM

markets

Is an opportunity to buy chip stocks nearing? These two big Wall Street banks are divided.

MarketWatchJuly 20, 2026 at 9:35 AM

markets

Why it’s time to retire the Magnificent Seven as a stock-market talking point, say these strategists

MarketWatchJuly 20, 2026 at 10:02 AM

← Back to all articles

Related Articles

Inflation is broadening out, says Goldman economist

Is an opportunity to buy chip stocks nearing? These two big Wall Street banks are divided.

Why it’s time to retire the Magnificent Seven as a stock-market talking point, say these strategists